DUBLIN, November 25, 2021--(BUSINESS WIRE)--The "Ragweed Pollen Hypersensitivity - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
This Ragweed pollen hypersensitivity - Pipeline Insight, 2021 report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Ragweed pollen hypersensitivity pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ragweed pollen hypersensitivity pipeline landscape is provided which includes the disease overview and Ragweed pollen hypersensitivity treatment guidelines.
The assessment part of the report embraces, in depth Ragweed pollen hypersensitivity commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ragweed pollen hypersensitivity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Ragweed pollen hypersensitivity R&D. The therapies under development are focused on novel approaches to treat/improve Ragweed pollen hypersensitivity.
Ragweed pollen hypersensitivity Emerging Drugs Chapters
This segment of the Ragweed pollen hypersensitivity report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ragweed pollen hypersensitivity Emerging Drugs
Ragweed MATA MPL: Allergy Therapeutics
Allergy Therapeutics is developing an Antiallergic to treat Ragweed pollen hypersensitivity. The therapy is currently in Phase III stage of clinical trial evaluation.
rag-ASIT+T: ASIT biotech
ASIT biotech is developing a therapy to treat Ragweed pollen hypersensitivity. The preclinical, clinical and production process of gp-ASIT+TM for the treatment of allergic rhinitis can be fully leveraged for the development of allergen fragments from other allergens such as house dust mite, ragweed and food allergens like peanut and eggwhite. The flexibility of the platform allows for adaption of the process to particular characteristics of a specific allergen.
Ragweed pollen hypersensitivity: Therapeutic Assessment
This segment of the report provides insights about the different Ragweed pollen hypersensitivity drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Ragweed pollen hypersensitivity
There are approx. 2+ key companies which are developing the therapies for Ragweed pollen hypersensitivity. The companies which have their Ragweed pollen hypersensitivity drug candidates in the most advanced stage, i.e. phase III include, Allergy Therapeutics.
This report covers around 2+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Ragweed pollen hypersensitivity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Ragweed pollen hypersensitivity: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ragweed pollen hypersensitivity therapeutic drugs key players involved in developing key drugs.
Ragweed pollen hypersensitivity Report Insights
Ragweed pollen hypersensitivity Pipeline Analysis
Impact of Drugs
Ragweed pollen hypersensitivity Report Assessment
Pipeline Product Profiles
Inactive drugs assessment
Key Questions Answered
How many companies are developing Ragweed pollen hypersensitivity drugs?
How many Ragweed pollen hypersensitivity drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ragweed pollen hypersensitivity?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ragweed pollen hypersensitivity therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Ragweed pollen hypersensitivity and their status?
What are the key designations that have been granted to the emerging drugs?
Ragweed MATA MPL
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ghnfme
View source version on businesswire.com: https://www.businesswire.com/news/home/20211125006119/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900